Evommune is licensing a VAV1 molecular glue degrader from China's Hinova to chase JAK-like efficacy in rheumatoid arthritis without the class's boxed safety warnings.
Top stories
Newsletter
Pipeline, markets, policy, and science. Once a week.
Its $1.275 billion upfront commitment to a Phase 1 program puts the spotlight on oral peptide developers, including Entera as it approaches Phase 3 in osteoporosis.
Petosemtamab plus Keytruda halved the risk of death versus Keytruda alone in first-line PD-L1-positive head and neck cancer, the first positive Phase 3 in that setting in several years, as Genmab races to replace Darzalex royalties.
Intismeran plus Keytruda cut melanoma recurrence or death risk by 42% versus Keytruda alone, a first Phase 3 win for a personalized mRNA vaccine. Moderna still fell as much as 25%.
In depth
Lilly's Jaypirca just won frontline CLL with a large survival edge, but only over chemoimmunotherapy the field is retiring. Lilly itself says the drug belongs in second line, and that sequencing logic shapes what the new label is really worth.
Read the storyThe FDA's 321-page review of Rasonque documents the survival win that earned a broad pancreatic cancer label, and the mutation subgroups whose response data ran against the drug.
Viatris is paying $1.65 billion for Pacira, roughly 2.2 times trailing revenue. The price only makes sense if you count EXPAREL's early 2030 licensed generic cliff and the four years of runway before it.
PhRMA sued CMS on October 7 over the GLOBE most-favored-nation rule for Medicare Part B. The final rule covers as few as four manufacturers and $440 million in projected savings. The suit's real target is the CMMI test authority beneath it.
A Nature paper finds that one arginine transfer RNA, tRNA1 Arg(UCU), keeps prostate tumors on androgen receptor signaling. When it falls, cells slip into a lineage-plastic, AR-inhibitor-resistant state.
